MabVax Therapeutics (MBVX) is Initiated by Laidlaw to Buy, Price Target at $2.50

MabVax Therapeutics (MBVX) was Initiated by Laidlaw to “Buy” and the brokerage firm has set the Price Target at $2.50. Laidlaw advised their investors in a research report released on Apr 13, 2016.

MabVax Therapeutics

Leave a Reply

MabVax Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on MabVax Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.